While Verve Therapeutics Inc has underperformed by -0.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VERV fell by -58.81%, with highs and lows ranging from $21.42 to $6.53, whereas the simple moving average fell by -50.83% in the last 200 days.
On April 08, 2024, H.C. Wainwright started tracking Verve Therapeutics Inc (NASDAQ: VERV) recommending Buy. A report published by Canaccord Genuity on April 13, 2023, Initiated its previous ‘Buy’ rating for VERV. Cantor Fitzgerald also rated VERV shares as ‘Neutral’, setting a target price of $21 on the company’s shares in an initiating report dated February 01, 2023. Goldman Initiated an Sell rating on December 15, 2022, and assigned a price target of $13. Credit Suisse initiated its ‘Neutral’ rating for VERV, as published in its report on October 06, 2022. Stifel’s report from August 25, 2022 suggests a price prediction of $56 for VERV shares, giving the stock a ‘Buy’ rating. BMO Capital Markets also rated the stock as ‘Outperform’.
Analysis of Verve Therapeutics Inc (VERV)
Further, the quarter-over-quarter increase in sales is 408.30%, showing a positive trend in the upcoming months.
One of the most important indicators of Verve Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -34.78% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 17.24, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and VERV is recording 1.28M average volume. On a monthly basis, the volatility of the stock is set at 7.08%, whereas on a weekly basis, it is put at 6.18%, with a loss of -12.63% over the past seven days. Furthermore, long-term investors anticipate a median target price of $31.22, showing growth from the present price of $6.64, which can serve as yet another indication of whether VERV is worth investing in or should be passed over.
How Do You Analyze Verve Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 30.25%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 72.32% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VERV shares are owned by institutional investors to the tune of 72.32% at present.
